Bryce Point Capital LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,054 shares of the company's stock, valued at approximately $492,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Huntington National Bank raised its holdings in Omnicell by 236.4% during the 4th quarter. Huntington National Bank now owns 1,359 shares of the company's stock valued at $61,000 after buying an additional 955 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Omnicell in the fourth quarter valued at $53,000. Alliancebernstein L.P. raised its stake in shares of Omnicell by 4.3% in the fourth quarter. Alliancebernstein L.P. now owns 55,922 shares of the company's stock valued at $2,490,000 after acquiring an additional 2,316 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Omnicell in the 4th quarter worth about $5,372,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Omnicell during the 4th quarter worth about $244,000. Hedge funds and other institutional investors own 97.70% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on OMCL. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Benchmark reissued a "buy" rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Finally, StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $51.00.
Check Out Our Latest Stock Report on OMCL
Omnicell Stock Up 7.1 %
Shares of Omnicell stock traded up $2.17 during trading on Wednesday, hitting $32.69. 1,287,556 shares of the stock traded hands, compared to its average volume of 526,477. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock's fifty day simple moving average is $36.84 and its 200 day simple moving average is $41.84. The firm has a market cap of $1.53 billion, a P/E ratio of 121.08, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75.
Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, equities analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
